Stock Price
25.00
Daily Change
-0.80 -3.10%
Monthly
1.96%
Yearly
-29.80%
Q2 Forecast
24.50

Ultragenyx Pharmaceutical reported $-1.84 in EPS Earnings Per Share for its fiscal quarter ending in March of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q1 Mar/2026 -1.84 -1.43 -1.57 May/05
FY2025Q4 Dec/2025 -1.29 -1.17 -1.39 Feb/12
FY2025Q3 Sep/2025 -1.81 -1.23 -1.40 Nov/04
FY2025Q2 Jun/2025 -1.17 -1.29 -1.52 Aug/05
FY2025Q1 Mar/2025 -1.57 -1.53 -2.03 May/06




Eps Change Date
Acadia Pharmaceuticals USD 0.02 1.58 Mar/2026
Agios Pharmaceuticals USD -1.69 0.17 Mar/2026
Alnylam Pharmaceuticals USD 1.99 0.74 Mar/2026
BioCryst Pharmaceuticals USD 1.17 1.1 Dec/2025
BioMarin Pharmaceutical USD 0.76 0.3 Mar/2026
Esperion Therapeutics USD 0.26 0.42 Dec/2025
Immunic USD -0.1 0.03 Dec/2025
Insmed USD -0.76 0.78 Mar/2026
Ionis Pharmaceuticals USD -0.56 0.85 Mar/2026
Karyopharm Therapeutics USD -2.22 2.07 Dec/2025
Kyowa Hakko Kirin JPY 22.99 42.8 Mar/2026
MacroGenics USD -0.58 0.36 Mar/2026
Moderna USD -3.4 1.29 Mar/2026
Neurocrine Biosciences USD 1.94 0.06 Mar/2026
PTC Therapeutics USD -0.03 1.64 Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 9.47 1.97 Mar/2026
Sarepta Therapeutics USD 3.16 6.74 Mar/2026
Ultragenyx Pharmaceutical USD -1.84 0.55 Mar/2026
Vertex Pharmaceuticals USD 4.47 0.56 Mar/2026
Xoma USD -1.59 2.43 Sep/2024